The US FDA has made no shortage of policy announcements during Scott Gottlieb's first year as commissioner, with the agency rolling out new measures to promote competition, curb the opioid epidemic and incentivize new drug development.
The hefty policy pronouncements coming out the agency have often won praise from supporters and critics alike, creating an impression...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?